Increased susceptibility of Alzheimer's disease temporal cortex to oxygen free radical-mediated processes

Free Radical Biology and Medicine

Volumn 23, Issue 2, 1997, Pages 183-190

  McIntosh, Laura J ^a   Trush, Michael A ^b   Troncoso, Juan C ^c  

^a STANFORD UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Alzheimer's Disease; Chemiluminescence; Lipid peroxidation; Temporal cortex; Vitamin E

Indexed keywords

ANTIOXIDANT; OXYGEN RADICAL; REACTIVE OXYGEN METABOLITE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ALZHEIMER DISEASE; ARTICLE; BRAIN HOMOGENATE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DIET SUPPLEMENTATION; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; NEOCORTEX; NEUROPROTECTION; PATHOGENESIS; PRIORITY JOURNAL; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIOXIDANTS; CEREBELLUM; CHEMILUMINESCENT MEASUREMENTS; FREE RADICALS; HUMANS; KINETICS; LIPID PEROXIDATION; MIDDLE AGED; REACTIVE OXYGEN SPECIES; TEMPORAL LOBE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; VITAMIN E;

EID: 0030910847     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(96)00573-4     Document Type: Article

References (41)

1. Dyrks T., Dyrks E., Hartmann T., Masters C., Beyreuther K. Radicals as mediators for the amyloidogenic transformation of βA4 -bearing APP fragments. Corain B. et al. Alzheimer's Disease: Advances in clinical and basic research. 1993;497-505 John Wiley & Sons Ltd, Chichester.
2. Mattson M., Goodman Y. Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res. 676:1995;219-224.
3. Kumar U., Dunlop D., Richardson J. Mitochondria from Alzheimer's fibroblasts show decreased uptake of calcium and increased sensitivity to free radicals. Life Sci. 54:1994;1855-1860.
4. Tesco G., Latorraca S., Piersanti P., Piancentini S., Amaducci L., Sorbi S. Alzheimer skin fibroblasts show increased susceptibility to free radicals. Mech. Ageing Dev. 66:1992;117-120.
5. Palmer A., Burns M. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res. 645:1994;338-342.
6. Subbarao K., Richardson J., Ang L. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J. Neurochem. 55:1990;342-345.
7. Hajimohammadreza I., Brammer M. Brain membrane fluidity and lipid peroxidation in Alzheimer's disease. Neurosci. Lett. 112:1990;333-337.
8. Benzi G., Moretti A. Are reactive oxygen species involved in Alzheimer's disease? Neurobiol. Aging. 16:1995;661-674.
9. Beal M. Aging, energy and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
10. Hensley K., Carney J., Mattson M., Aksenova M., Harris M., Wu J., Floyd R., Butterfield D. A model for β -amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc. Natl. Acad. Sci. USA. 91:1994;3270-3274.
11. Klegeris A., Walker D., McGeer P. Activation of macrophages by Alzheimer beta amyloid peptide. Biochem. Biophys. Res. Commun. 199:1994;984-991.
12. Parker W., Parks J., Filley C., Kleinschmidt-DeMasters B. Electron transport chain defects in Alzheimer's disease brain. Neurology. 44:1994;1090-1096.
13. Reichmann H., Florke S., Hebenstreit G., Schrubar H., Reiderer P. Analyses of energy metabolism and mitochondrial genome in post-mortem brain from patients with Alzheimer's disease. J. Neurol. 240:1993;377-380.
14. Corral-Debrinski M., Horton T., Lott M., Shoffner J., Beal M., Wallace D. Mitochondrial DNA deletions in human brain: Regional variability and increase with advanced age. Nat. Genet. 2:1992;324-329.
15. Mecocci P., MacGarvey U., Beal M. Oxidative damage to mitochondrial DNA is increased in Alzheimer's Disease. Ann. Neurol. 36:1994;747-751.
16. Cadenas E. Oxidative stress and formation of excited species. Sies H. Oxidative stress. 1985;Academic Press, London.
17. Khachaturian Z. S. Diagnosis of Alzheimer's disease. Arch. Neurol. 42:1985;1097-1105.
18. Mirra, S.; Heyman, A.; McKeel, D.; Sumi, S. M.; Crain, B. J.; Brownlee, L. M.; Vogel, F. S.; Hughes, J. P.; van Belle, G.; Berg, L.; participating CERAD neuropathologists. The consortium to establish a registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurol. 41:479-486; 1991.
19. Buege J. A., Aust S. D. Microsomal lipid peroxidation. Meth. Enzymol. 52:1978;302-310.
20. Gsell W., Conrad R., Hickethier M., Sofic E., Frolich L., Wichart I., Jellinger K., Moll G., Ransmayr G., Beckmann H., Riederer P. Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J. Neurochem. 64:1995;1216-1223.
21. Balazs L., Leon M. Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem. Res. 19:1994;1131-1137.
22. Marklund S., Adolfsson R., Gottfries C., Winblad B. Superoxide dismutase isoenzymes in normal brains and in brains from patients with dementia of Alzheimer type. J. Neurol. Sci. 67:1985;319-325.
23. Furuta A., Price D., Pardo C., Troncoso J., Xu Z., Taniguchi N., Martin L. Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am. J. Pathol. 146:1995;357-367.
24. Serra J., Famulari A., Kohan S., Marschoff E., Dominguez R., Lustig E. D. Copper-zinc superoxide dismutase activity in red blood cells in probable Alzheimer's patients and their first-degree relatives. J. Neurol. Sci. 122:1994;179-188.
25. Perrin R., Briancon S., Jeandel C., Artur Y., Minn A., Penin F., Siest G. Blood activity of Cu/Zn superoxide dismutase, glutathione peroxidase and catalase in Alzheimer's disease: A case-control study. Gerontology. 36:1990;306-313.
26. Pappolla M., Omar R., Kim K., Robakis N. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease. Am. J. Pathol. 140:1992;621-628.
27. Zemlan F., Thienhaus O., Bosmann H. Superoxide dismutase activity in Alzheimer's disease: Possible mechanism for paired helical filament formation. Brain Res. 476:1989;160-162.
28. Kuiper M., Mulder C., Kamp G.V., Scheltens P., Wolters E. Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease and multiple system atrophy. J. Neural Transm. Parkinson's Dis. Dementia Sect. 7:1994;109-114.
29. Loeffler D., Dimaggio A., Juneau P., Brickman C., Mashour G., Finkelman J., Pomara N., LeWitt P. Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. Alzheimer Dis. Associated-Dis. 8:1994;190-197.
30. Jellinger K., Paulus W., Grundke-Iqbal I., Reiderer P., Youdim M. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. Parkinson's Dis. Dementia Sec. 2:1990;327-340.
31. Dedman D., Treffry A., Candy J., Taylor G., Morris C., Bloxham C., Perry R., Edwardson J., Harrison P. Iron and aluminum in relation to brain ferritin in normal individuals and Alzheimer's disease and chronic renal-dialysis patients. Biochem. J. 287:1992;509-514.
32. Connor J., Snyder B., Beard J., Fine R., Mufson E. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J. Neurosci. Res. 31:1992;327-335.
33. Guan Z., Soderberg M., Sindelar P., Edlund C. Content and fatty acid composition of cardiolipin in the brain of patients with Alzheimer's disease. Neurochem. Int. 25:1994;295-300.
34. Svennerholm L., Gottfries C. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (Type I) and demyelination in late-onset form (Type II). J. Neurochem. 62:1994;1039-1047.
35. Söderberg M., Edlund E., Kristensson K., Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids. 26:1991;421-425.
36. Nitsch R., Blusztajn J., Pittas A., Slack B., Growdon J., Wurtman R. Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl. Acad. Sci. USA. 89:1992;1671-1675.
37. Kwee I., Nakada T., Ellis W. Elevation in relative levels of brain membrane unsaturated fatty acids in Alzheimer's disease: High resolution proton spectroscopic studies of membrane lipid extracts. Magn. Reson. Med. 21:1991;49-54.
38. Adams J., Klaidman L., Odunze I., Shen H., Miller C. Alzheimer's and Parkinson's disease: Brain levels of glutathione, glutathione disulfide, and vitamin E. Mol. Chem. Neuropathol. 14:1991;213-226.
39. Jeandel C., Nicolas M., Dubois F., Nabet-Belleville F., Penin F., Cuny G. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology. 35:1989;275-282.
40. Metcalfe T., Bowen D., Muller D. Vitamin E concentrations in human brain of patients with Alzheimer's disease, fetuses with Down's syndrome, centenarians, and controls. Neurochem. Res. 14:1989;1209-1212.
41. Tohgi H., Abe T., Nakanishi M., Hamato F., Sasaki K., Takahashi S. Concentrations of alpha-tocopherol and its quinone derivative in cerebrospinal fluid from patients with vascular dementia of the Binswanger type and Alzheimer type dementia. Neurosci. Lett. 174:1994;73-76.